ReviewClinical and translational medicine2026
Piezo1 in digestive homeostasis and disease: Barrier function, immune signalling, cellular injury and metabolism.
Review in Clinical and translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundPiezo1 is a mechanosensitive cation channel that converts stretch, compression, and shear stress into calcium-dependent signals. This narrative review evaluates how Piezo1 contributes to digestive physiology and disease and why divergent outcomes arise across experimental contexts. MAIN BODY: We searched PubMed/MEDLINE, Embase, Web of Science, and Scopus from database inception to 15 July 2026, prioritising primary studies that used Piezo1-specific genetic or pharmacological interventions. Piezo1-specific evidence supports roles in epithelial junctional adaptation, mucus production, stem-cell renewal, immune activation, injury, fibrosis, and gastrointestinal endocrine signalling. A contextual framework based on cell identity and state, mechanical stimulus, and tissue or disease phase helps explain these divergent effects. Transient physiological activation may support homeostasis and repair, whereas persistent or excessive activation can promote Ca
conclusionTherapeutic translation is limited by non-selective tool compounds, broad tissue expression and the need for targeted delivery and phase-appropriate modulation. Piezo1 is therefore best viewed as a context-dependent mechanotransducer rather than a uniformly pathogenic target.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.